E1	Condition:T1 Name:T2 Duration:E4
E3	Condition:T3 Name:T4 Temporality:E11
E5	Condition:T5 Name:T6
E7	Procedure:T7 Name:T8 Temporality:E48 Temporality2:E49
E9	Procedure:T9 Name:T10 Temporality:E14
E10	Eq-Comparison:T36 Operator:T11 Value:T28
E11	Eq-Comparison:T37 Operator:T12 Temporal-Unit:T21 Value:T30
E12	Eq-Comparison:T38 Operator:T13 Temporal-Unit:T22 Value:T31
E13	Eq-Comparison:T39 Operator:T16 Temporal-Unit:T24 Value:T33
E14	Eq-Comparison:T40 Operator:T17 Temporal-Unit:T25 Value:T34
E15	Eq-Comparison:T41 Operator:T18 Temporal-Unit:T26 Value:T35
E2	Study:T42
E4	Eq-Comparison:T43 Operator:T44 Temporal-Unit:T19 Value:T27
E6	Eq-Comparison:T45 Value:T46 Temporal-Unit:T20
E8	Temporal-Connection:T47 Arg:E4 Arg2:E2
E16	Condition:T48 Name:T49 Stage:E17
E17	Eq-Comparison:T50 Unit:T51 Value:T52 Value2:T54 Operator:T53
E18	Study:T55
E19	Temporal-Connection:T56 Arg:E16 Arg2:E18
E20	Observation:T57 Name:T58 Eq-Comparison:E10
E21	Study:T59
E22	Temporal-Connection:T29 Arg:E20 Arg2:E21
E23	Immunization:T60
E24	Risk:T61 Risk-For:E5
E25	Organism:T62 Name:T63
E26	Study:T64 Study-Of:E27
E27	Drug:T65
E28	Temporal-Connection:T66 Arg:E11
E29	Temporal-Connection:T67 Arg:E26
E30	Or:T68 Arg:E28 Arg2:E29
E31	Condition:T69
E32	Condition:T70 Name:T71 Temporality:E33
E33	Eq-Comparison:T72 Temporal-Period:T73
E36	Or:T76 Arg:E33 Arg2:E34
E37	Eq-Comparison:T77 Temporal-Period:T78
E38	Condition:T79 Name:T80 Temporality:E37
E39	Condition:T81 Name:T82
E40	Or:T83 Arg:E38 Arg2:E39
E41	Study:T84
E42	Temporal-Connection:T85 Arg:E12 Arg2:E41
E43	Procedure:T86
E44	Coreference:T87 Refers-To:E39 Temporality:E12
E45	Negation:T88 Negates:E44
E46	And:T89 Arg:E43 Arg2:E45
E47	Exception:T90 From:E39 Except:E43
E48	Eq-Comparison:T91 Temporal-Period:T92
E49	Eq-Comparison:T93 Operator:T14 Temporal-Unit:T23 Value:T32
E50	Study:T94
E51	Temporal-Connection:T95 Arg:E49 Arg2:E50
E52	Condition:T96 Name:T97 Temporality:E53
E53	Eq-Comparison:T98 Temporal-Period:T99
E54	Drug:T15 Name:T100 Temporality:E13
E55	Study:T101
E56	Temporal-Connection:T102 Arg:E13 Arg2:E55
E57	Study:T103
E58	Temporal-Connection:T104 Arg:E14 Arg2:E57
E59	Drug:T105 Name:T106 Temporality:E15
E60	Study:T107
E61	Temporal-Connection:T108 Arg:E15 Arg2:E60
E62	Drug:T109 Name:T110
E63	Drug:T111 Name:T112
E64	Eq-Comparison:T113 Temporal-Period:T114
E65	Procedure:T115 Temporality:E64
E34	Modifier:T74
E35	Organism:T75 Name:T116
E66	Modifier:T117 Modifies:T6
T1	Condition 40 57	Myasthenia Gravis
T2	Condition-Name 40 57	Myasthenia Gravis
T3	Condition 357 381	meningococcal infections
T4	Condition-Name 357 381	meningococcal infections
T5	Condition 484 493	infection
T6	Condition-Name 484 493	infection
T7	Procedure 759 769	thymectomy
T8	Procedure-Name 759 769	thymectomy
T9	Procedure 996 1011	plasma exchange
T10	Procedure-Name 996 1011	plasma exchange
T11	Eq-Operator 289 290	≥
T12	Eq-Operator 382 388	within
T13	Eq-Operator 715 716	≥
T14	Eq-Operator 770 776	within
T16	Eq-Operator 947 953	within
T17	Eq-Operator 1012 1018	within
T18	Eq-Operator 1071 1077	within
T19	Eq-Temporal-Unit 69 75	months
T20	Eq-Temporal-Unit 81 85	days
T21	Eq-Temporal-Unit 391 396	years
T22	Eq-Temporal-Unit 719 724	years
T23	Eq-Temporal-Unit 784 790	months
T24	Eq-Temporal-Unit 956 961	weeks
T25	Eq-Temporal-Unit 1021 1026	weeks
T26	Eq-Temporal-Unit 1080 1086	months
T27	Eq-Value 67 68	6
T28	Eq-Value 291 292	6
T30	Eq-Value 389 390	3
T31	Eq-Value 717 718	5
T32	Eq-Value 781 783	12
T33	Eq-Value 954 955	4
T34	Eq-Value 1019 1020	4
T35	Eq-Value 1078 1079	6
T36	Eq-Comparison 289 292	≥ 6
T37	Eq-Comparison 382 396	within 3 years
T38	Eq-Comparison 715 724	≥ 5 years
T39	Eq-Comparison 947 961	within 4 weeks
T40	Eq-Comparison 1012 1026	within 4 weeks
T41	Eq-Comparison 1071 1086	within 6 months
T42	Study 112 121	Screening
T43	Eq-Comparison 58 75	at least 6 months
T44	Eq-Operator 58 66	at least
T45	Eq-Comparison 77 85	180 days
T46	Eq-Value 77 80	180
T47	Temporal-Connection 87 92	prior
T48	Condition 168 231	Myasthenia Gravis Foundation of America Clinical Classification
T49	Condition-Name 168 231	Myasthenia Gravis Foundation of America Clinical Classification
T50	Eq-Comparison 232 246	Class II to IV
T51	Eq-Unit 232 237	Class
T52	Eq-Value 238 240	II
T53	Eq-Operator 241 243	to
T54	Eq-Value 244 246	IV
T55	Study 250 259	screening
T56	Temporal-Connection 247 249	at
T57	Observation 266 272	MG-ADL
T58	Observation-Name 266 272	MG-ADL
T59	Study 296 305	screening
T29	Temporal-Connection 293 295	at
T60	Immunization 338 348	Vaccinated
T61	Risk 462 466	risk
T62	Organism 495 509	N meningitidis
T63	Organism-Name 495 509	N meningitidis
T64	Study 437 442	study
T65	Drug 443 447	drug
T66	Temporal-Connection 397 405	prior to
T67	Temporal-Connection 410 412	at
T68	Or 407 409	or
T69	Condition 532 550	Medical Conditions
T70	Condition 580 587	thymoma
T71	Condition-Name 580 587	thymoma
T72	Eq-Comparison 560 566	active
T73	Eq-Temporal-Period 560 566	active
T76	Or 567 569	or
T77	Eq-Comparison 589 596	History
T78	Eq-Temporal-Period 589 596	History
T79	Condition 600 616	thymic carcinoma
T80	Condition-Name 600 616	thymic carcinoma
T81	Condition 620 637	thymic malignancy
T82	Condition-Name 620 637	thymic malignancy
T83	Or 617 619	or
T84	Study 732 741	screening
T85	Temporal-Connection 725 731	before
T86	Procedure 670 679	treatment
T87	Coreference 700 710	recurrence
T88	Negation 685 687	no
T89	And 680 684	with
T90	Exception 638 644	unless
T91	Eq-Comparison 748 755	History
T92	Eq-Temporal-Period 748 755	History
T93	Eq-Comparison 770 790	within the 12 months
T94	Study 800 809	screening
T95	Temporal-Connection 791 796	prior
T96	Condition 842 851	infection
T97	Condition-Name 842 851	infection
T98	Eq-Comparison 816 823	History
T99	Eq-Temporal-Period 816 823	History
T15	Drug 929 946	IV immunoglobulin
T100	Drug-Name 929 946	IV immunoglobulin
T101	Study 965 978	randomization
T102	Temporal-Connection 962 964	of
T103	Study 1030 1043	randomization
T104	Temporal-Connection 1027 1029	of
T105	Drug 1061 1070	rituximab
T106	Drug-Name 1061 1070	rituximab
T107	Study 1090 1099	screening
T108	Temporal-Connection 1087 1089	of
T109	Drug 1160 1181	complement inhibitors
T110	Drug-Name 1160 1181	complement inhibitors
T111	Drug 1196 1206	eculizumab
T112	Drug-Name 1196 1206	eculizumab
T113	Eq-Comparison 1136 1144	previous
T114	Eq-Temporal-Period 1136 1144	previous
T115	Procedure 1145 1154	treatment
T74	Modifier 570 579	untreated
T75	Organism 827 841	N meningitidis
T116	Organism-Name 827 841	N meningitidis
T117	Modifier 470 483	meningococcal
A1	Eq-Operator-Value T11 GTEQ
A2	Eq-Operator-Value T12 LTEQ
A3	Eq-Operator-Value T13 GTEQ
A4	Eq-Operator-Value T14 LTEQ
A6	Eq-Operator-Value T16 LTEQ
A7	Eq-Operator-Value T17 LTEQ
A8	Eq-Operator-Value T18 LTEQ
A9	Eq-Temporal-Unit-Value T19 month
A10	Eq-Temporal-Unit-Value T20 day
A11	Eq-Temporal-Unit-Value T21 year
A12	Eq-Temporal-Unit-Value T22 year
A13	Eq-Temporal-Unit-Value T23 month
A14	Eq-Temporal-Unit-Value T24 week
A15	Eq-Temporal-Unit-Value T25 week
A16	Eq-Temporal-Unit-Value T26 month
A17	Eq-Operator-Value T44 GTEQ
A18	Temporal-Connection-Type-Value E8 before
A19	Eq-Operator-Value T53 BETWEEN
A20	Temporal-Connection-Type-Value E19 during
A21	Observation-Type-Value T58 clinical-score
A22	Temporal-Connection-Type-Value E22 during
A23	Temporal-Connection-Type-Value E28 before
A24	Temporal-Connection-Type-Value E29 during
A25	Eq-Temporal-Period-Value T73 present
A26	Eq-Temporal-Period-Value T78 past
A27	Temporal-Connection-Type-Value E42 before
A28	Eq-Temporal-Period-Value T92 past
A29	Temporal-Connection-Type-Value E51 before
A30	Eq-Temporal-Period-Value T99 past
A5	Temporal-Connection-Type-Value E56 before
A31	Temporal-Connection-Type-Value E58 before
A32	Temporal-Connection-Type-Value E61 before
A33	Eq-Temporal-Period-Value T114 past
R1	Equivalent-To Arg1:E6 Arg2:E4
R2	Treatment-For Arg1:E23 Arg2:E3
R4	Treatment-For Arg1:E27 Arg2:E5
R6	Treatment-For Arg1:E43 Arg2:E39
R7	Example-Of Arg1:E63 Arg2:E62
R8	Using Arg1:E65 Arg2:E62
R5	Abbrev-Of Arg1:E34 Arg2:E32
R3	Caused-By Arg1:E5 Arg2:E25
R9	Caused-By Arg1:E52 Arg2:E35